<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <script src="https://cdnjs.cloudflare.com/ajax/libs/Chart.js/3.7.0/chart.min.js"></script>
    <title>MS Clinical Intelligence Dashboard</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
            font-family: system-ui, -apple-system, sans-serif;
        }

        body {
            background-color: #f5f7fa;
            min-height: 100vh;
            padding: 2rem;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            background-color: white;
            border-radius: 1rem;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            padding: 2rem;
        }

        .header {
            text-align: center;
            margin-bottom: 3rem;
            padding: 2rem;
            background: linear-gradient(135deg, #2c3e50, #3498db);
            border-radius: 0.5rem;
            color: white;
        }

        .header h1 {
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: 0.5rem;
        }

        .section-title {
            font-size: 1.5rem;
            color: #2c3e50;
            margin-bottom: 2rem;
            padding-bottom: 0.5rem;
            border-bottom: 2px solid #3498db;
        }

        .timeline {
            position: relative;
            padding: 2rem 0;
            border-bottom: 2px solid #3498db;
        }

        .timeline-line {
            position: absolute;
            top: 50%;
            left: 0;
            right: 0;
            height: 4px;
            background: #070707;
            transform: translateY(-50%);
        }

        .timeline-points {
            position: relative;
            display: flex;
            justify-content: space-between;
            margin: 0 2rem;
        }

        .timeline-point {
            position: relative;
            display: flex;
            flex-direction: column;
            align-items: center;
            width: 200px;
        }

        .point {
            width: 20px;
            height: 20px;
            border-radius: 50%;
            margin: 1rem 0;
            z-index: 1;
        }

        .year {
            font-weight: 600;
            margin-bottom: 1rem;
            color: #2c3e50;
        }

        .description {
            text-align: center;
            font-size: 0.7rem;
            font-weight: bold ;
            color: #555;
            margin-top: 1rem;
            padding: 0.5rem;
            border-radius: 0.5rem;
            min-height: 80px;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .timeline-point:nth-child(1) .point { background-color: #3498db; }
        .timeline-point:nth-child(2) .point { background-color: #2ecc71; }
        .timeline-point:nth-child(3) .point { background-color: #e74c3c; }
        .timeline-point:nth-child(4) .point { background-color: #f1c40f; }
        .timeline-point:nth-child(5) .point { background-color: #9b59b6; }
        .timeline-point:nth-child(6) .point { background-color: #1abc9c; }

        .timeline-point:nth-child(odd) .description {
            background-color: #f8f9fa;
        }

        .timeline-point:nth-child(even) .description {
            background-color: #e9ecef;
        }
        .timeline-point {
            position: relative;
            display: flex;
            flex-direction: column;
            align-items: center;
            width: 200px;
        }

        .timeline-point::before {
            content: '';
            position: absolute;
            top: 40%;
            width: 3px;
            height: 30px;
            background-color: #3498db;
            z-index: 0;
        }

        .container_grid {
            max-width: 1200px;
            margin: 20px auto; /* Added 20px margin on top */
            padding: 20px;
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }


        .moa-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 30px;
        }

        .moa-button {
            background: white;
            border: 1px solid #e1e4e8;
            border-radius: 8px;
            padding: 15px;
            display: flex;
            align-items: center;
            cursor: pointer;
            transition: all 0.3s ease;
            position: relative;
            overflow: hidden;
        }

        .moa-button::after {
            content: '';
            position: absolute;
            width: 100%;
            height: 100%;
            top: 0;
            left: 0;
            background: rgba(255,255,255,0.1);
            transform: translateX(-100%);
            transition: transform 0.3s ease;
        }

        .moa-button:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }

        .moa-button:hover::after {
            transform: translateX(0);
        }

        .moa-icon {
            width: 40px;
            height: 40px;
            border-radius: 8px;
            margin-right: 15px;
            flex-shrink: 0;
        }

        .immunomodulators { background-color: #4299e1; }
        .btk-inhibitors { background-color: #48bb78; }
        .s1p-modulators { background-color: #ed8936; }

        .moa-name {
            flex-grow: 1;
            font-weight: 600;
            color: #2d3748;
        }

        .dropdown-arrow {
            color: #718096;
            transition: transform 0.3s ease;
        }

        .active .dropdown-arrow {
            transform: rotate(180deg);
        }

        .moa-details {
            background: white;
            border-radius: 8px;
            padding: 20px;
            margin-top: 20px;
            display: none;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
        }

        .metrics-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 20px;
            margin-bottom: 30px;
        }

        .metric-card {
            background: #f8fafc;
            border-radius: 8px;
            padding: 20px;
            text-align: center;
            cursor: pointer;
            position: relative;
            display: inline-block;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            transition: transform 0.2s;

        }
        .metric-card:hover {
    transform: translateY(-2px);
}

/* Tooltip styling */
.metric-card::after {
    content: attr(data-tooltip);
    position: absolute;
    bottom: 130%; 
    left: 50%;
    transform: translateX(-50%);
    background-color: #6d6d6d;
    color: #fff;
    padding: 10px 14px;
    font-weight: bold;
    border-radius: 6px;
    font-size: 14px;
    white-space: nowrap;
    opacity: 0;
    visibility: hidden;
    transition: opacity 0.3s ease, transform 0.3s ease;
    box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
    z-index: 1;
    pointer-events: none;
}

/* Tooltip arrow */
.metric-card::before {
    content: "";
    position: absolute;
    bottom: 120%; 
    left: 50%;
    transform: translateX(-50%);
    border-width: 6px;
    border-style: solid;
    border-color: transparent transparent #333 transparent;
    opacity: 0;
    visibility: hidden;
    transition: opacity 0.3s ease;
}

/* Show tooltip on hover */
.metric-card:hover::after,
.metric-card:hover::before {
    opacity: 1;
    visibility: visible;
    transform: translate(-50%, -5px); /* Adds a slight lift to the tooltip */
}

        .metric-value {
            font-size: 24px;
            font-weight: 700;
            color: #2d3748;
            margin: 10px 0;
        }

        .charts-section {
            display: grid;
            grid-template-columns: 1fr 1fr 1fr;
            gap: 20px;
            margin-bottom: 30px;
        }

        .chart-container {
            background: white;
            border-radius: 8px;
            padding: 20px;
            height: 350px; 
    width: 100%; 
    box-sizing: border-box;
        }

        @media (max-width: 768px) {
            .charts-section {
                grid-template-columns: 1fr;
            }
            
            .metrics-grid {
                grid-template-columns: 1fr;
            }
        }
        .container-tb {
        max-width: 1200px;
        margin: 0 auto;
        background: white;
        border-radius: 12px;
        box-shadow: 0 1px 3px rgba(0,0,0,0.1);
        padding: 20px;
    }

        table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
        }

        th {
            background: #f1f5f9;
            padding: 16px;
            text-align: left;
            font-weight: 600;
            color: #334155;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 16px;
            border-bottom: 1px solid #e2e8f0;
            vertical-align: top;
        }

        .drug-row {
            cursor: pointer;
            transition: all 0.2s ease;
        }

        .drug-row:hover {
            background-color: #f8fafc;
        }

        .drug-row.active {
            background-color: #f1f5f9;
            border-bottom: none;
        }

        .drug-name {
            display: flex;
            align-items: center;
            gap: 12px;
            font-weight: 500;
            color: #1e40af;
        }

        .drug-icon {
            width: 24px;
            height: 24px;
            display: flex;
            align-items: center;
            justify-content: center;
            transition: transform 0.3s ease;
            color: #64748b;
        }

        .drug-row.active .drug-icon {
            transform: rotate(180deg);
        }

        .drug-insights {
            display: none;
            background: #f8fafc;
        }

        .drug-insights td {
            padding: 0;
        }

        .drug-insights.show {
            display: table-row;
        }

        .insights-container {
            padding: 20px;
            border-top: 2px solid #e2e8f0;
        }

        .insights-section {
            background: white;
            border-radius: 8px;
            padding: 20px;
            margin-bottom: 16px;
            box-shadow: 0 1px 2px rgba(0,0,0,0.05);
        }

        .insights-section:last-child {
            margin-bottom: 0;
        }

        .insights-section h4 {
            color: #334155;
            margin: 0 0 12px 0;
            font-size: 1rem;
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .insights-section h4::before {
            content: "•";
            color: #3b82f6;
        }

        .insights-section p {
            margin: 0;
            color: #475569;
        }

        .trial-button {
            background: #e2e8f0;
            border: 1px solid #cbd5e1;
            padding: 8px 16px;
            border-radius: 6px;
            margin-right: 8px;
            margin-top: -2px;
            margin-bottom: 6px;
            cursor: pointer;
            font-size: 0.875rem;
            color: #334155;
            transition: all 0.2s ease;
            font-weight: 500;
        }

        .trial-button:hover {
            background: #cbd5e1;
            border-color: #94a3b8;
        }

        .trial-button.active {
            background: #bfdbfe;
            border-color: #60a5fa;
            color: #1e40af;
        }

        .trial-insights {
            display: none;
            background: white;
        }

        .trial-insights.show {
            display: table-row;
        }

        .trial-insights .insights-section {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
        }

        .phase-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 5px;
            padding: 6px 12px;
            border-radius: 6px;
            background: #f9f9f9;
            color: #1e40af;
            font-size: 0.875rem;
            font-weight: 500;
        }

        .company-cell {
            color: #64748b;
            text-shadow: #2d3748;
        }

        /* Additional styles for better visibility of active states */
        .drug-row td {
            border-bottom: 1px solid #e2e8f0;
            transition: border-color 0.2s ease;
        }

        .drug-row.active td {
            border-bottom-color: transparent;
        }

        .trial-insights td {
            padding: 0 16px 16px 16px;
        }
        .timeline-container-inner {
            max-width: 1200px;
            margin: 200px auto 20px auto;
        }

        .timeline-inner {
            position: relative;
            padding: 60px 0;
        }

        /* Main horizontal line */
        .timeline-inner::before {
            content: '';
            position: absolute;
            margin-top: -115px;
            left: 0;
            right: 0;
            top: 50%;
            height: 4px;
            background: #3498db;
            transform: translateY(-50%);
        }

        .timeline-items-inner {
            display: flex;
            justify-content: space-between;
            position: relative;
        }

        .timeline-item-inner {
            flex: 1;
            position: relative;
            padding: 0 20px;
            text-align: center;
        }

        /* Dots on the line */
        .timeline-dot-inner {
            width: 20px;
            height: 20px;
            background: #fff;
            border: 4px solid #3498db;
            border-radius: 50%;
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            z-index: 1;
        }

        /* Content boxes */
        .timeline-content-inner {
            background: white;
            padding: 20px;
            border-radius: 8px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            margin: 50px 0;
            position: relative;
        }

        /* Alternating content boxes */
        .timeline-item-inner:nth-child(odd) .timeline-content-inner {
            margin-top: 50px;
        }

        .timeline-item-inner:nth-child(even) .timeline-content-inner {
            margin-top:-180px;
        }

        /* Vertical connector lines */
        .timeline-item-inner:nth-child(odd) .timeline-content-inner::before {
            content: '';
            position: absolute;
            top: -30px;
            left: 50%;
            width: 1px;
            height: 30px;
            background: #3498db;
            transform: translateX(-50%);
        }

        .timeline-item-inner:nth-child(even) .timeline-content-inner::before {
            content: '';
            position: absolute;
            bottom: -30px;
            left: 50%;
            width: 1px;
            height: 30px;
            background: #3498db;
            transform: translateX(-50%);
        }

        .timeline-year-inner {
            font-size: 1rem;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 10px;
        }

        .timeline-description-inner {
            color: #666;
            line-height: 1.5;
            font-size: 0.60rem;
            font-weight: bold;
        }

        @media (max-width: 768px) {
            .timeline-items-inner {
                flex-direction: column;
            }

            .timeline-item-inner {
                margin-bottom: 40px;
            }

            .timeline-item-inner:nth-child(even) .timeline-content-inner,
            .timeline-item-inner:nth-child(odd) .timeline-content-inner {
                margin-top: 20px;
            }
        }
        .latest-insights {
            max-width: 1200px;
            margin: 30px auto;
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
            padding: 25px;
        }

        .latest-insights h2 {
            color: #2d3748;
            margin-bottom: 20px;
            font-size: 1.5rem;
            font-weight: 600;
        }

        .insight-category {
            margin-bottom: 15px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            overflow: hidden;
        }

        .insight-header {
            display: flex;
            align-items: center;
            justify-content: space-between;
            padding: 15px 20px;
            background-color: #f8fafc;
            cursor: pointer;
            transition: background-color 0.3s ease;
        }

        .insight-header:hover {
            background-color: #f1f5f9;
        }

        .header-title {
            font-weight: 600;
            color: #2d3748;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .header-title .category-icon {
            width: 24px;
            height: 24px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 6px;
        }

        .clinical .category-icon {
            background-color: #ebf5ff;
            color: #3182ce;
        }

        .regulatory .category-icon {
            background-color: #f0fff4;
            color: #38a169;
        }

        .safety .category-icon {
            background-color: #fff5f5;
            color: #e53e3e;
        }

        .market .category-icon {
            background-color: #faf5ff;
            color: #805ad5;
        }

        .toggle-btn {
            width: 24px;
            height: 24px;
            border-radius: 50%;
            background-color: #ffffff;
            border: 1px solid #e2e8f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            transition: all 0.3s ease;
            font-size: 18px;
            color: #64748b;
        }

        .toggle-btn:hover {
            background-color: #f8fafc;
            transform: scale(1.1);
        }

        .insight-content {
            max-height: 0;
            overflow: auto;
            transition: max-height 0.3s ease-out;
            background-color: white;
        }

        .insight-content.active {
            max-height: 500px;
            transition: max-height 0.5s ease-in;
        }

        .insight-list {
            padding: 20px;
        }

        .insight-item {
            display: flex;
            gap: 15px;
            padding: 12px;
            border-bottom: 1px solid #f1f5f9;
        }

        .insight-item:last-child {
            border-bottom: none;
        }

        .insight-date {
            min-width: 100px;
            color: #64748b;
            font-size: 0.9rem;
        }

        .insight-description {
            color: #4a5568;
            line-height: 1.5;
            flex-grow: 1;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 0.75rem;
            font-weight: 500;
            margin-left: 8px;
        }

        .badge.new {
            background-color: #ebf5ff;
            color: #3182ce;
        }

        .badge.update {
            background-color: #f0fff4;
            color: #38a169;
        }
        .styled-link {
        text-decoration: none; 
        color: inherit; 
        transition: color 0.3s ease;
    }

    .styled-link:hover .description {
        color: #ff0088;
        cursor: pointer;
        font-size: bold;
    }
    .ms-research-item {
    padding-top: 10px; 
    padding-left: 15px;
}
.link-box {
    display: inline-block;
    padding: 2px 4px;
    font-size: 10px;
    font-weight: bold;
    background-color: #9f9f9f; 
    color: rgb(255, 255, 255);
    text-decoration: none;
    border-radius: 15px; 
    border: 1px solid #9f9f9f; 
}

.link-box:hover {
    background-color: #000000; /* Darker green on hover */
}

    </style>
</head>
<body>
    <div class="container">
        <header class="header">
            <h1>Clinical Intelligence - Multiple Sclerosis</h1>
        </header>

        <section>
            <h2 class="section-title">MS Treatment Development Timeline</h2>
            <div class="timeline">
                <div class="timeline-line"></div>
                <div class="timeline-points">
                    <div class="timeline-point">
                        <div class="year">2019</div>
                        <div class="point"></div>
                        <a href="https://academic.oup.com/ajhp/article/81/2/37/7287407" class="styled-link" target="_blank">
                            <div class="description">BTK inhibitors transform treatment.</div>
                        </a>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2020</div>
                        <div class="point"></div>
                        <a href="https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.799138/full" class="styled-link" target="_blank"><div class="description">Improved anti-CD20 targeting.</div></a>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2021</div>
                        <div class="point"></div>
                    <a href="https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.824926/full" class="styled-link" target="_blank"><div class="description">New Safer S1P modulators.</div></a>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2022</div>
                        <div class="point"></div>
                    <a href="https://academic.oup.com/ajhp/article/81/2/37/7287407" class="styled-link" target="_blank"><div class="description">Remyelination breakthrough.</div></a>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2023</div>
                        <div class="point"></div>
                    <a href="https://journals.lww.com/nrronline/fulltext/2023/02000/microglia_depletion_as_a_therapeutic_strategy_.5.aspx" class="styled-link" target="_blank"><div class="description">Microglial modulation advances.</div></a>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2024</div>
                        <div class="point"></div>
                    <a href="https://academic.oup.com/ajhp/article/81/2/37/7287407" class="styled-link" target="_blank"><div class="description">Development of Combined immune-regeneration therapy.</div></a>
                    </div>
                </div>
            </div>
        </section>
    </div>

    <div class="container_grid">
        <h2 class="section-title">Mechanism Of Actions</h2>
        <div class="moa-grid">
            <div class="moa-button" onclick="toggleMOA('anticd20', this)">
                <div class="moa-icon immunomodulators"></div>
                <span class="moa-name">Anti CD20 monoclonal antibody</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('btk', this)">
                <div class="moa-icon btk-inhibitors"></div>
                <span class="moa-name">BTK Inhibitors</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon s1p-modulators"></div>
                <span class="moa-name">S1P Modulators</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon immunomodulators"></div>
                <span class="moa-name">DHODH Inhibitors</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon btk-inhibitors"></div>
                <span class="moa-name">Immunomodulators</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon s1p-modulators"></div>
                <span class="moa-name">Anti CD40L monoclonal antibody </span>
                <span class="dropdown-arrow">▼</span>
            </div>
        </div>

        <!-- BTK Inhibitors -->
        <div id="btk-details" class="moa-details">
            <h3 class="section-title">BTK Inhibitors</h3>
            <div class="metrics-grid">
                <div class="metric-card" data-tooltip="10 Ongoing Trials in BTK Inhibitors">
                    <h3>Total Trials</h3>
                    <div class="metric-value">10</div>
                </div>
                <div class="metric-card" data-tooltip="Roche, Sanofi, Novartis, Biogen, Beijing InnoCare">
                    <h3>Total Competitors</h3>
                    <div class="metric-value">5</div>
                </div>
                <div class="metric-card" data-tooltip="Remibrutinib, Fenebrutinib, Tolebrutinib, Orelabrutinib, Biib091">
                    <h3>Drug Count</h3>
                    <div class="metric-value">5</div>
                </div>
            </div>

            <div class="charts-section">
                <div class="chart-inside">
                    <div class="chart-container">
                        <canvas id="btk-phase-chart"></canvas>
                    </div>
                </div>
                <div class="chart-middle">
                    <div class="chart-container">
                        <canvas id="btk-market-chart"></canvas>
                    </div>
                </div>
                <div class="chart-last">
                    <div class="chart-container">
                        <canvas id="btk-stacked-chart"></canvas>
                    </div>
                </div>
                
            </div>
            <h2 class="section-title">BTK Inhibitors Time Line</h2>
            <div class="timeline-container-inner">
                <div class="timeline-inner">
                    <div class="timeline-items-inner">
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2019</div>
                                <div class="timeline-description-inner">
                                    <a href="https://www.neurologylive.com/view/evobrutinib-paves-the-way-for-btk-inhibitors-in-multiple-sclerosis" class="styled-link" target="_blank">Evobrutinib demonstrated Phase 2 success in reducing MS lesions and relapses.</a>
                                </div>
                            </div>
                        </div>
            
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2020</div>
                                <div class="timeline-description-inner">
                                    <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2801597" class="styled-link" target="_blank">Long-term safety data boosts Evobrutinib’s potential, driving BTK inhibitor research.</a>
                                </div>
                            </div>
                        </div>
            
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2021</div>
                                <div class="timeline-description-inner">
                                    <a href="https://pharmsight.com/resources/blog/the-role-of-btk-inhibitors-in-ms-and-et/" class="styled-link" target="_blank">Fenebrutinib and Tolebrutinib enter Phase 3 trials targeting MS relapse and progression.</a>
                                </div>
                            </div>
                        </div>
            
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2022</div>
                                <div class="timeline-description-inner">
                                    <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2801597" class="styled-link" target="_blank">
                                        Safety concerns lead to FDA hold on Tolebrutinib trials, emphasizing safety adjustments.</a>
                                </div>
                            </div>
                        </div>
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2023</div>
                                <div class="timeline-description-inner">
                                    <a href="https://www.neurologylive.com/view/bruton-tyrosine-kinase-inhibitors-new-hope-management-progression-ms" class="styled-link" target="_blank">Fenebrutinib excels in relapsing MS, Tolebrutinib resumes with safety updates.</a>
                                </div>
                            </div>
                        </div>
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2024</div>
                                <div class="timeline-description-inner">
                                    <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2801597" class="styled-link" target="_blank">Final Phase 3 data from Fenebrutinib and Evobrutinib may lead to regulatory submissions.</a>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>        

            <h2 class="section-title">Drug / Molecule Details</h2>
            <div class="container">
                <table>
                    <thead>
                        <tr>
                            <th>Drug Name</th>
                            <th>Company</th>
                            <th>Trial Count</th>
                            <th>Trial IDs and Phase</th>
                        </tr>
                    </thead>
                    <tbody>
                        <!-- Drug 1 -->
                        <tr class="drug-row" data-drug="remibrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Remibrutinib
                                </div>
                            </td>
                            <td class="company-cell">Novartis</td>
                            <td><span class="phase-badge">2</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05156281">NCT05156281<span class="phase-badge">Phase - III</span></button>
                                <button class="trial-button" data-trial="NCT05147220">NCT05147220<span class="phase-badge">Phase - III</span></button>
                            </td>
                        </tr>
                        
                        <tr id="remibrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h3>KOL Opinion</h3>
                                        <br>
                                        <h4>Dr. Laura Airas, Professor of Neuroimmunology, Turku University Hospital</h4>
                                        <p><li class="ms-research-item">Highlighted remibrutinib's positive safety profile across autoimmune disorders, indicating suitability for MS.</li>
                                        <li class="ms-research-item">Emphasized that Selective BTK targeting may reduce inflammatory nerve cell damage in MS.</li>
        
                                        <li class="ms-research-item">Also emphasized about its minimal adverse effects, supporting long-term safety. <a href="https://www.neurologylive.com/view/btk-inhibitor-remibrutinib-demonstrates-positive-safety-various-autoimmune-disorders" class="link-box" target="_blank"> Neurology live</a>
                                        </li>
                                        
                                        </p>
                                    </div>

                                </div>
                            </td>
                        </tr>
        
                        <!-- Trial Insights -->
                        <tr id="NCT05156281-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05156281</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The Phase 3 trial NCT05156281, led by Novartis, is evaluating remibrutinib's efficacy in reducing relapse rates and disability progression in relapsing multiple sclerosis (MS), comparing it to teriflunomide over two years. Interim findings show remibrutinib has a favorable safety profile across autoimmune conditions, reinforcing its promise for MS. The trial is currently recruiting participants and will track MRI changes, neurofilament levels, and physical function as secondary outcomes​
                                    </p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT05147220-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05147220</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The Phase III trials REMODEL I and II (NCT05147220) are evaluating the efficacy and safety of remibrutinib, a BTK inhibitor, in patients with relapsing multiple sclerosis (MS). These studies aim to compare remibrutinib with teriflunomide, a standard MS treatment, focusing on safety, tolerability, and efficacy across a large patient population. Both trials are being conducted globally with active recruitment in multiple countries, and preliminary discussions highlight remibrutinib’s potential in modulating B-cell-driven inflammation, a critical factor in MS progression​</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT72382624-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05147220</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug -2 -->
                        <tr class="drug-row" data-drug="fenebrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Fenebrutinib
                                </div>
                            </td>
                            <td class="company-cell">Roche</td>
                            <td><span class="phase-badge">3</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05119569">NCT05119569<span class="phase-badge">Phase - II</span></button>
                                <button class="trial-button" data-trial="NCT04586023">NCT04586023<span class="phase-badge">Phase - II</span></button>
                                <button class="trial-button" data-trial="NCT04586010">NCT04586010<span class="phase-badge">Phase - III</span></button>
                            </td>
                        </tr>
                        <tr id="fenebrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h3>KOL Opinion</h3>
                                        <br>
                                        <h4>Dr. Levi Garraway, Chief Medical Officer, Roche</h4>
                                        <p><li class="ms-research-item">Fenebrutinib could suppress nearly all disease activity in MS patients</li>
                                        <li class="ms-research-item">Potential to become a major treatment option if Phase III results confirm early findings. 
                                            <a href="https://multiplesclerosisnewstoday.com/news-posts/2024/09/06/r1-year-fenebrutinib-inhibits-nearly-all-signs-relapsing-ms-trial/" class="link-box" target="_blank">Multiple Sclerosis News Today</a>
                                            <a href="https://www.clinicaltrialsarena.com/news/roche-fenebrutinib-relapsing-multiple-sclerosis/" class="link-box" target="_blank">Clinical Trials Arena</a></li></p>
                                    </div>
                            </td>
                        </tr>
        
                        <tr id="NCT05119569-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05119569</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>The Phase II FENopta study (NCT05119569) investigated Roche’s drug fenebrutinib in relapsing MS patients, showing a 69% reduction in new gadolinium-enhancing lesions and a 74% reduction in NET2 lesions compared to placebo over 12 weeks. By Week 12, reductions reached 90% for Gd+ lesions and 95% for NET2 lesions. Mean CSF concentration of fenebrutinib was 43.1 ng/mL, well above active ranges in blood assays, indicating effective central nervous system penetration. The drug demonstrated a favorable safety profile with no serious adverse events reported.</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04586023-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04586023</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>The trial for fenebrutinib (NCT04586023), a selective Bruton’s tyrosine kinase (BTK) inhibitor by Roche, targeted patients with progressive multiple sclerosis (MS). Results from the Phase II study showed positive outcomes, with fenebrutinib achieving the primary endpoint of reducing new gadolinium-enhancing T1 brain lesions, a marker of active inflammation, and the secondary endpoint of reducing T2 brain lesions, which indicate disease burden. No new safety concerns were identified, reinforcing fenebrutinib's established safety profile. These results underscore fenebrutinib's potential as a treatment to address inflammation and disability progression in MS</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04586010-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04586010</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The clinical trial NCT04586010, known as the FENtrepid study, investigates the efficacy of fenebrutinib in treating primary progressive multiple sclerosis (PPMS). This large, randomized, double-blind trial aims to enroll up to 946 patients, testing fenebrutinib against both placebo and ocrelizumab over 120 weeks. The primary goal is to assess disability progression over a 12-week period, with secondary measures including changes in brain volume and physical impacts reported by participants. Early data shows fenebrutinib’s ability to reduce new inflammatory lesions and suggests it penetrates the brain effectively, targeting key immune cells like B-cells and microglia, which drive inflammation in MS</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 3 -->
                        <tr class="drug-row" data-drug="tolebrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Tolebrutinib
                                </div>
                            </td>
                            <td class="company-cell">Sanofi</td>
                            <td><span class="phase-badge">3</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT03996291">NCT03996291<span class="phase-badge">Phase - III</span></button>
                                <button class="trial-button" data-trial="NCT04458051">NCT04458051<span class="phase-badge">Phase - III</span></button>
                                <button class="trial-button" data-trial="NCT04411641">NCT04411641<span class="phase-badge">Phase - III</span></button>
                            </td>
                        </tr>
                        <tr id="tolebrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h3>KOL Opinion</h3>
                                        <br>
                                        <h4>Dr. Jiwoh Oh, University of Toronto</h4>
                                        <p><li class="ms-research-item">Emphasized the drug’s ability to
                                            stabilize relapse rates.</li>
                                        <li class="ms-research-item">Effective in
                                            limiting new lesions
                                            in MS patients.</li></p>
                                        <br>
                                        <h4>Dr. Erik Wallström, Sanofi</h4>
                                        <p><li class="ms-research-item">Highlighted
                                            brain penetration
                                            as a key feature.</li>
                                        <li class="ms-research-item">Significant impact on
                                            MS disease progression.</li>
                                        <li class="ms-research-item">Modulates
                                            inflammatory signaling
                                            within the brain.
                                            <a href="https://www.neurologylive.com/view/open-label-analysis-highlights-long-term-safety-btk-inhibitor-tolebrutinib" class="link-box" target="_blank">Neurology live</a>
                                            <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-10-13-07-00-00-2313117" class="link-box" target="_blank">Sanofi Immunology</a>
                                        </li></p>
                                    </div>
                            </td>
                        </tr>
        
                        <tr id="NCT03996291-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT03996291</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The open-label extension trial (NCT03996291) of tolebrutinib showed promising results for people with relapsing forms of multiple sclerosis (MS). In this study, tolebrutinib led to significant reductions in relapse rates, stabilized disability progression, and reduced brain lesion counts over time. The trial findings support tolebrutinib's potential as a beneficial oral BTK inhibitor for addressing smoldering neuroinflammation in relapsing MS. Sanofi aims to advance its regulatory plans based on this positive safety and efficacy profile.</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04458051-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04458051</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The PERSEUS trial is a Phase 3 study evaluating tolebrutinib, Sanofi's BTK inhibitor, in patients with primary progressive multiple sclerosis (PPMS). It aims to determine if tolebrutinib can delay confirmed disability progression compared to a placebo. The trial results, expected in late 2025, will provide additional insights into the drug’s effectiveness in slowing disability progression in PPMS, addressing an unmet need for treatments in progressive MS.</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04411641-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04411641</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The HERCULES Phase 3 trial evaluated tolebrutinib's effects on disability progression in non-relapsing secondary progressive MS (SPMS). Results showed a 31% reduction in disability progression risk and an 88% improvement in six-month confirmed disability improvement rates for patients on tolebrutinib compared to placebo. Although it reduced brain lesions by 38%, tolebrutinib did not significantly slow brain tissue loss. Safety monitoring was increased due to liver enzyme concerns</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 4 -->
                        <tr class="drug-row" data-drug="orelabrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Orelabrutinib
                                </div>
                            </td>
                            <td class="company-cell">Beijing InnoCare Pharma</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT04711148">NCT04711148<span class="phase-badge">Phase - II</span></button>
                            </td>
                        </tr>
                        <tr id="orelabrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h3>KOL Opinion</h3>
                                        <br>
                                        <h4>Dr. Alfred Sandrock, Head of Research and Development, Biogen</h4>
                                        <p><li class="ms-research-item">Emphasized
                                            orelabrutinib’s potential
                                            to provide significant clinical benefits for MS patients.</li>
                                        <li class="ms-research-item">By specifically targeting the
                                            underlying biology of MS
                                            , orelabrutinib aims to address key drivers of disease activity.</li>
                                            <li class="ms-research-item">This approach could lead to
                                                improved treatment outcomes
                                                by directly impacting disease mechanisms rather than just managing symptoms.
                                            
                                                <a href="https://investors.biogen.com/news-releases/news-release-details/biogen-and-innocare-announce-license-and-collaboration-agreement" class="link-box" target="_blank">Biogen Investors</a>
                                            
                                            </li>
                                        </p>
                                    </div>
                                    
                            </td>
                        </tr>
        
                        <tr id="NCT04711148-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04711148</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>InnoCare Pharma's Phase 2 trial results show that orelabrutinib led to a significant, dose-dependent reduction in new active brain lesions in RRMS patients, with up to a 92.1% reduction in the highest dose group (80 mg daily). This 12-week interim analysis indicates that orelabrutinib met its primary objective, supporting further development. Compared to similar BTK inhibitors, it demonstrated competitive efficacy and a favorable safety profile.</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 5 -->
                        <tr class="drug-row" data-drug="biib091">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Biib091
                                </div>
                            </td>
                            <td class="company-cell">Biogen</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05798520">NCT05798520<span class="phase-badge">Phase - II</span></button>
                            </td>
                        </tr>
                        <tr id="biib091-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h3>KOL Opinion</h3>
                                        <br>
                                        <h4>Dr. Diana Gallagher, Head of MS and Immunology, Biogen</h4>
                                        <p><li class="ms-research-item">Highlighted the potential of
                                            BIIB091
                                            as an innovative treatment option for MS.</li>
                                        <li class="ms-research-item">Based on our early SAD (single-ascending dose) and MAD (multiple-ascending dose) studies, we’re going to try to target a dose selection that will get us 90% [B cell] suppression on B cell activation.
                                            <a href="https://www.neurologylive.com/view/phase-2-fusion-trial-btk-inhibitor-biib091-diana-gallagher" class="link-box" target="_blank">Neurology live</a>

                                        </li></p>
                                    </div>
                            </td>
                        </tr>
        
                        <tr id="NCT05798520-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05798520</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>The Phase 2 FUSION trial (NCT05798520) for Biogen's BIIB091 is currently in progress and focuses on relapsing forms of multiple sclerosis (MS). The study is assessing both BIIB091 as a monotherapy and in combination with Diroximel Fumarate (DRF), an approved MS therapy. Early-stage studies (SAD and MAD) have shown promising results in terms of B-cell suppression, which is critical in MS treatment. The primary endpoint in the first part of the trial is safety, while the second part focuses on MRI-based reductions in brain inflammation. The trial is expected to enroll 275 patients, with results expected by 2026</p>
                                </div>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="latest-insights">
                <h2>Latest Insights</h2>
                
                <!-- Clinical Breakthroughs -->
                <div class="insight-category">
                    <div class="insight-header clinical" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">🔬</span>
                            Clinical Breakthroughs
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <!-- <span class="insight-date">Oct 15, 2024</span> -->
                                <div class="insight-description">
                                <strong> Clinical Efficacy: Several BTK inhibitors are undergoing investigation</strong> 
                                    <br>
                                    <li><span class="insight-date"> <strong>Evobrutinib (Merck KGaA/EMD Serono): </strong> Showed acceptable tolerability and maintained efficacy in a phase 2 study over 2.5 years, although it failed to meet primary endpoints in subsequent phase 3 trials.</span>
                                    <a href="https://www.neurologylive.com/view/bruton-tyrosine-kinase-inhibitors-new-hope-management-progression-ms" class="link-box" target="_blank">Neurologylive</a>
                                    </li>
                                    <li><span class="insight-date"> <strong>Fenebrutinib (Roche): </strong> Demonstrated significant reductions in MRI markers of MS activity and a favorable safety profile, although it faced safety concerns related to liver function.</span>
                                        <a href="https://pharmsight.com/resources/blog/the-role-of-btk-inhibitors-in-ms-and-et/" class="link-box" target="_blank">PharmaSite</a></li>
                                    <li><span class="insight-date"> <strong>Tolebrutinib (Sanofi):  </strong>Reported a 60 mg/d dosage reduced T1 gadolinium-enhancing lesions by approximately 85%, with stable Expanded Disability Status Scale (EDSS) scores over time.</span>
                                        <a href="https://jamanetwork.com/journals/jamaneurology/article-abstract/2801597" class="link-box" target="_blank">JAMA Network</a></li>
                                    <li><span class="insight-date"> <strong>Orelabrutinib (Beijing InnoCare Pharma):  </strong>In a Phase 2 trial, Orelabrutinib demonstrated a significant reduction in new active brain lesions by 90% over a 12-week period. This promising result supports further development of Orelabrutinib for MS.</span>
                                        <a href="https://multiplesclerosisnewstoday.com/news-posts/2023/03/29/orelabrutinib-reduces-rrms-brain-lesions-90-percent-trial-analysis/" class="link-box" target="_blank">multiplesclerosisnewstoday</a></li>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            
                <!-- Safety and Tolerability -->
                <div class="insight-category">
                    <div class="insight-header regulatory" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">🛡️</span>
                            Safety and Tolerability
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <div class="insight-description">
                                    <strong>Novartis (Remibrutinib)</strong>
                                    <li>Early data indicate that remibrutinib is generally well-tolerated, with adverse events reportedly balanced between the treatment and control groups.</li>
                                    <li>Remibrutinib has shown minimal impact on liver function, which is a promising sign in the context of long-term use for chronic conditions like RMS.</li>
                                    <li>The most common adverse events noted across similar trials include mild to moderate issues, with no significant safety concerns emerging thus far.
                                        <a href="https://www.novartis.com/clinicaltrials/study/nct05156281" class="link-box" target="_blank">Novartis</a>
                                        <a href="https://ichgcp.net/clinical-trials-registry/NCT05156281" class="link-box" target="_blank">ICHGCP</a>
                                    </li>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    <strong>Roche (Fenebrutinib)</strong>
                                    <li>Fenebrutinib demonstrated a positive safety profile, with most adverse events being mild to moderate, including instances of urinary tract infections, pharyngitis, and COVID-19 infections among participants.</li>
                                    <li>In long-term extension studies, liver enzyme elevations were observed in a few cases.</li>
                                    <li>No new or unexpected safety concerns have emerged, and the safety profile of fenebrutinib is consistent with earlier trials.
                                        <a href="https://medically.roche.com/content/dam/pdmahub/restricted/neurology/actrim-forum-2024/ACTRIMS-Forum-2024-poster-jiwon-the-safety-profile-of-fenebrutinib-in-patients.pdf" class="link-box" target="_blank">Medically
                                        </a>
                                        <a href="https://www.neurologylive.com/view/multiple-sclerosis-suppression-disability-observed-new-fenebrutinib-phase-2-data" class="link-box" target="_blank">Neurologylive</a>
                                    </li>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    <strong>Sanofi (Tolebrutinib)</strong>
                                    <li>The FDA issued a partial hold on U.S. enrollment in 2022 due to liver injury cases, primarily in participants with pre-existing liver risk factors. The liver issues resolved after treatment was stopped, and Sanofi enhanced liver monitoring and adjusted participant criteria to mitigate risks.
                                        <a href="https://www.sanofi.com/assets/dotcom/pressreleases/2022/2022-10-26-11-00-00-2541624-en.pdf" class="link-box" target="_blank">Medically
                                        </a>
                                    </li>
                                    <li>Enrollment continues outside the U.S. under updated protocols, with stringent monitoring to assess long-term safety.
                                        <a href="https://multiplesclerosisnewstoday.com/news-posts/2024/09/23/ectrims-2024-tolebrutinib-target-smoldering-inflammation-ms/" class="link-box" target="_blank">Multiplesclerosisnewstoday</a>
                                    </li>
                                    <li>Prior Phase 2 results showed tolebrutinib was generally well-tolerated, but the recent concerns underscore the need for comprehensive long-term safety evaluation
                                        <a href="https://multiplesclerosisnewstoday.com/news-posts/2022/07/01/phase-3-tolebrutinib-trials-pause-us-enrollment-over-safety-concerns/" class="link-box" target="_blank">Multiplesclerosisnewstoday</a>
                                    </li>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    <strong>Beijing InnoCare (Orelabrutinib)</strong>
                                    <li>Unlike some BTK inhibitors, orelabrutinib has so far not been associated with significant liver toxicity, a factor important for its consideration as a long-term treatment for MS patients.
                                        <a href="https://multiplesclerosisnewstoday.com/news-posts/2021/07/14/biogen-strikes-deal-innocare-orelabrutinib-potential-oral-ms-therapy-phase-2-trial/" class="link-box" target="_blank">Multiplesclerosisnewstoday
                                        </a>
                                    </li>
                                    <li>Patients in the trial have tolerated the drug well, with most adverse events (AEs) being mild to moderate. Notably, the most common AEs across other trials included manageable hematologic issues (e.g., low blood counts) and mild infections.
                                        <a href="https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-orelabrutinib-for-relapsed-refractory-mcl" class="link-box" target="_blank">Multiplesclerosisnewstoday
                                        </a>
                                    </li>
                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    <strong>Biogen (BIIB091)</strong>
                                    <li>Based Phase 1 study of BIIB091,the results showed that BIIB091 was generally well-tolerated, with no significant safety concerns observed during the initial phase of trials.
                                        <a href="https://investors.biogen.com/news-releases/news-release-details/new-data-actrims-ectrims-meeting-showcase-safety-and-efficacy" class="link-box" target="_blank">Biogen Investors
                                        </a>
                                    </li>

                                    <li>GI side effects were reported to be manageable, which is important given that oral BTK inhibitors like BIIB091 are expected to be beneficial in treating MS while avoiding more severe immune cell depletion
                                        <a href="https://www.biogentriallink.com/content/dam/global-development/general/biogen-trial-link/educational/en-us/pdf/patient_information/NCT05798520_Patient_Study_Information.pdf" class="link-box" target="_blank">Neurologylive</a>
                                    </li>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            
                <!-- Regulatory Milestones -->
                <div class="insight-category">
                    <div class="insight-header safety" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">📋</span>
                            Regulatory Milestones
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <div class="insight-description">
                                <strong> 1.	Tolebrutinib (Sanofi)</strong> 
                                    <br>

                                <li>In 2022, a partial FDA clinical hold was implemented due to concerns about drug-induced liver injury, affecting the approval timeline.</li>
                                    
                                    <li>Sanofi aims to file for regulatory approval by the end of 2024.

                                        <a href="https://pharmaphorum.com/news/sanofis-tolebrutinib-cuts-ms-progression-31-trial" class="link-box" target="_blank">Pharmaphorum</a>
                                    <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-10-13-07-00-00-2313117" class="link-box" target="_blank"> Sanofi Immunology</a>
                                
                                    </li>
                                    <br>
                                
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                <strong> 2.	Fenebrutinib (Genentech/Roche)</strong> 
                                    <br>
                                <li>Fenebrutinib is advancing through Phase III trials, with results expected by late 2025.</li>

                                <li>The FENhance 1 & 2 trials are evaluating fenebrutinib in relapsing multiple sclerosis (RMS).
                                    <a href="https://www.globenewswire.com/news-release/2024/09/04/2940215/0/en/Roche-s-fenebrutinib-demonstrated-near-complete-suppression-of-disease-activity-and-disability-progression-for-up-to-48-weeks-in-patients-with-relapsing-multiple-sclerosis.html" class="link-box" target="_blank">GlobeNewswire</a>
                                    <a href="https://pharmaphorum.com/news/roche-trumpets-new-fenebrutinib-data-relapsing-ms" class="link-box" target="_blank"> Pharmaphorum</a>
                                </li>
                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                <strong> 3.	Orelabrutinib (InnoCare)</strong> 
                                    
                                <li>Orelabrutinib is approved in China for treating relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).</li>
                                    
                                <li>Currently advancing through global trials, with a Phase III trial initiated for primary progressive multiple sclerosis (PPMS).

                                    <a href="https://www.innocarepharma.com/en/development/Orelabrutinib" class="link-box" target="_blank">Innocare Pharma</a>
                                    <a href="https://www.innocarepharma.com/en/news/activity/en020240908-Phase-III-trial-of-orelabrutinib-for-the-treatment-of-PPMS" class="link-box" target="_blank"> Innocare Pharma</a>
                                
                                </li>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                <strong> 4.	Remibrutinib </strong> 
                                    
                                <li>Novartis plans regulatory submissions for remibrutinib in 2024, starting with CSU.</li>
                                <li>Submission based on positive results from ongoing trials.</li>   
                                <li>The application for multiple sclerosis is still under clinical investigation, with trial completion expected in 2030.

                                    <a href="https://pharmaphorum.com/news/novartis-cues-filings-remibrutinib-chronic-hives" class="link-box" target="_blank">Pharmaphorum</a>
                                    <a href="https://www.clinicalresearch.com/find-trials/Study/NCT05156281" class="link-box" target="_blank"> Clinical Research</a>
                                
                                </li>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                <strong> 5.	BIIB091</strong> 
                                    
                                <li>The trial is currently in Phase 2, with an estimated completion date of November 2026.</li>
                                    
                                <li>No major regulatory submissions have been made yet, as the focus remains on gathering safety and efficacy data.

                                    <a href="https://ichgcp.net/clinical-trials-registry/NCT05798520" class="link-box" target="_blank">ICHGCP</a>
                                    <a href="https://www.clinicalresearch.com/find-trials/Study/NCT05798520" class="link-box" target="_blank"> IClinical Research</a>
                                
                                </li>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    <script>
        function toggleMOA(moa, button) {
            const details = document.getElementById(`${moa}-details`);
            const allButtons = document.querySelectorAll('.moa-button');
            
            // Remove active class from all buttons
            allButtons.forEach(btn => btn.classList.remove('active'));
            
            if (details.style.display === 'none' || !details.style.display) {
                // Hide all MOA details first
                document.querySelectorAll('.moa-details').forEach(detail => {
                    detail.style.display = 'none';
                });
                
                details.style.display = 'block';
                button.classList.add('active');
                initializeCharts(moa);
            } else {
                details.style.display = 'none';
                button.classList.remove('active');
            }
        }

        document.addEventListener('DOMContentLoaded', function() {
            // Drug row click handlers
            document.querySelectorAll('.drug-row').forEach(row => {
                row.addEventListener('click', function(e) {
                    if (e.target.classList.contains('trial-button')) {
                        return; // Don't handle drug row click if trial button was clicked
                    }
                    
                    const drugId = this.getAttribute('data-drug');
                    const insights = document.getElementById(`${drugId}-insights`);
                    
                    // Close all other drug insights
                    // document.querySelectorAll('.drug-insights').forEach(insight => {
                    //     if (insight !== insights) {
                    //         insight.classList.remove('show');
                    //     }
                    // });
                    
                    // Remove active class from all rows
                    document.querySelectorAll('.drug-row').forEach(r => {
                        if (r !== this) {
                            r.classList.remove('active');
                        }
                    });
                    
                    // Toggle current drug insights
                    this.classList.toggle('active');
                    insights.classList.toggle('show');
                    
                    // Close all trial insights when toggling drug insights
                    document.querySelectorAll('.trial-insights').forEach(insight => {
                        insight.classList.remove('show');
                    });
                    document.querySelectorAll('.trial-button').forEach(button => {
                        button.classList.remove('active');
                    });
                });
            });

            // Trial button click handlers
            document.querySelectorAll('.trial-button').forEach(button => {
                button.addEventListener('click', function(e) {
                    e.stopPropagation(); // Prevent drug row click
                    
                    const trialId = this.getAttribute('data-trial');
                    const insights = document.getElementById(`${trialId}-insights`);
                    
                    // Close all other trial insights
                    // document.querySelectorAll('.trial-insights').forEach(insight => {
                    //     if (insight !== insights) {
                    //         insight.classList.remove('show');
                    //     }
                    // });
                    
                    // Remove active class from all trial buttons
                    document.querySelectorAll('.trial-button').forEach(btn => {
                        if (btn !== this) {
                            btn.classList.remove('active');
                        }
                    });
                    
                    // Toggle current trial insights and button state
                    this.classList.toggle('active');
                    insights.classList.toggle('show');
                });
            });
        });


        function initializeCharts(moa) {
    // Phase Distribution Chart
    const phaseCtx = document.getElementById(`${moa}-phase-chart`).getContext('2d');
    new Chart(phaseCtx, {
        type: 'bar',
        data: {
            labels: ['Phase 1', 'Phase 2', 'Phase 3'],
            datasets: [{
                label: 'Number of Trials',
                data: [0, 4, 6],
                backgroundColor: '#4299e1'
            }]
        },
        options: {
            responsive: true,
            maintainAspectRatio: false,
            plugins: {
                title: {
                    display: true,
                    text: 'Trial Phase Distribution'
                }
            }
        }
    });

    // Market Share Chart
    const marketCtx = document.getElementById(`${moa}-market-chart`).getContext('2d');
    new Chart(marketCtx, {
        type: 'pie',
        data: {
            labels: ['Sanofi', 'Novartis', 'Beijing InnoCare Pharma', 'Roche', 'Biogen'],
            datasets: [{
                data: [30, 20, 10, 30, 10],
                backgroundColor: ['#4299e1', '#48bb78', '#ed8936', '#9f7aea', '#f56565']
            }]
        },
        options: {
            responsive: true,
            maintainAspectRatio: false,
            plugins: {
                title: {
                    display: true,
                    text: 'Market Share Distribution-% (Based on trial count)'
                },
                tooltip: {
                    callbacks: {
                        label: function(tooltipItem) {
                            const dataset = tooltipItem.dataset;
                            const total = dataset.data.reduce((acc, value) => acc + value, 0);
                            const currentValue = dataset.data[tooltipItem.dataIndex];
                            const percentage = Math.floor((currentValue / total) * 100);
                            return `${tooltipItem.label}: ${percentage}%`;
                        }
                    }
                }
            }
        }
    });

    // Stacked Bar Chart
    const stackedCtx = document.getElementById(`${moa}-stacked-chart`).getContext('2d');
    new Chart(stackedCtx, {
        type: 'bar',
        data: {
            labels: ['Sanofi', 'Novartis', 'Beijing InnoCare Pharma', 'Roche', 'Biogen'],  // Competitors on X-axis
            datasets: [{
                label: 'Phase 1 Trials',
                data: [0, 0, 0, 0, 0], 
                backgroundColor: '#4299e1'
            }, {
                label: 'Phase 2 Trials',
                data: [1, 0, 1, 1, 1], // Number of Phase 2 trials for each company
                backgroundColor: '#48bb78'
            }, {
                label: 'Phase 3 Trials',
                data: [2, 2, 0, 2, 0], // Number of Phase 3 trials for each company
                backgroundColor: '#9f7aea'
            }]
        },
        options: {
            responsive: true,
            maintainAspectRatio: false,
            plugins: {
                title: {
                    display: true,
                    text: 'Trials by Competitor and Phase'
                }
            },
            scales: {
                x: {
                    stacked: true,
                },
                y: {
                    stacked: true,
                    beginAtZero: true, // Ensure the Y-axis starts from 0
                }
            }
        }
    });
}

        function toggleInsight(header) {
            const content = header.nextElementSibling;
            const toggleBtn = header.querySelector('.toggle-btn');
            const allContents = document.querySelectorAll('.insight-content');
            const allToggleBtns = document.querySelectorAll('.toggle-btn');

            // Toggle current section
            content.classList.toggle('active');
            toggleBtn.textContent = content.classList.contains('active') ? '−' : '+';
        }

    </script>

</body>
</html>
